European Neurology
Original Paper
Neuropsychiatric Profiles of Patients with InsulinomasDing Y.a · Wang S.a · Liu J.a · Yang Y.a · Liu Z.a · Li J.a · Zhang B.b · Chen Y.c · Ding M.aDepartments of aNeurology, bSurgery, and cRadiology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: May 15, 2009
Accepted: October 18, 2009
Published online: December 23, 2009
Issue release date: January 2010
Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 2
ISSN: 0014-3022 (Print)
eISSN: 1421-9913 (Online)
For additional information: https://www.karger.com/ENE
Abstract
Background/Aims: Insulinoma is a rare and potentially curable disease. It is often misdiagnosed as neurological or psychiatric disorder. This study was performed to characterize the neuropsychiatric symptoms (PNS) of the patients with insulinoma from a regional clinical center. Methods: All medical records of the patients with histopathologically identified insulinoma were reviewed during the period from 1998 to 2008. A case-control analysis was performed to compare the demographic data, details of clinical presentation, biochemical findings, tumor localization, and intraoperative findings between the patients with and without a prior misdiagnosis. Results: Among 42 patients with insulinoma, 25 patients with PNS were initially misdiagnosed as having a neurological or psychiatric disease, while 17 patients with no PNS were correctly diagnosed. Most (64%) of PNS cases were not diagnosed correctly until 12 months after the first consultation. In patients with PNS that remained undiagnosed for at least 5 years, the most frequent symptoms were confusion, convulsion, and visual disturbances. Twelve cases of PNS were initially misdiagnosed as epilepsy and 3 of them showed epileptiform discharges on electroencephalography. Conclusions: Episodic hypoglycemia induced by insulinoma can greatly mimic neurological and psychiatric presentation. A thorough history taking and inpatient assessment are necessary in evaluating recurrent neurological and psychiatric symptoms.
© 2009 S. Karger AG, Basel
Related Articles:
References
- Boukhman MP, Karam JH, Shaver J, Siperstein AE, Duh QY, Clark OH: Insulinoma – experience from 1950 to 1995. West J Med 1998;169:98–104.
- O’Sullivan SS, Redmond J: Insulinoma presenting as refractory late-onset epilepsy. Epilepsia 2005;46:1690–1691.
- Graves TD, Gandhi S, Smith SJ, Sisodiya SM, Conway GS: Misdiagnosis of seizures: insulinoma presenting as adult-onset seizure disorder. J Neurol Neurosurg Psychiatry 2004;75:1091–1092.
- Bazil CW, Pack A: Insulinoma presenting as seizure disorder. Neurology 2001;56:817–818.
- Wang S, Hu HT, Wen SQ, Wang ZJ, Zhang BR, Ding MP: An insulinoma with clinical and electroencephalographic features resembling complex partial seizures. J Zhejiang Univ Sci B 2008;9:496–499.
- Shanmugam V, Zimnowodzki S, Curtin J, Gorelick PB: Hypoglycemic hemiplegia: insulinoma masquerading as stroke. J Stroke Cerebrovasc Dis 1997;6:368–369.
- Nakamura Y, Doi R, Kohno Y, Shimono D, Kuwamura N, Inoue K, Koshiyama H, Imamura M: High-dose calcium stimulation test in a case of insulinoma masquerading as hysteria. Endocrine 2002;19:127–130.
- Kapoor RR, James C, Hussain K: Advances in the diagnosis and management of hyperinsulinemic hypoglycemia. Nat Clin Pract Endocrinol Metab 2009;5:101–112.
- Dizon AM, Kowalyk S, Hoogwerf BJ: Neuroglycopenic and other symptoms in patients with insulinomas. Am J Med 1999;106:307–310.
- Stefanini P, Carboni M, Patrassi N, Basoli A: Beta-islet cell tumors of the pancreas: results of a study on 1,067 cases. Surgery 1974;75:597–609.
- Mitrakou A, Fanelli C, Veneman T, Perriello G, Calderone S, Platanisiotis D, Rambotti A, Raptis S, Brunetti P, Cryer P, et al: Reversibility of unawareness of hypoglycemia in patients with insulinomas. N Engl J Med 1993;329:834–839.
- DeRosa MA, Cryer PE: Hypoglycemia and the sympathoadrenal system: neurogenic symptoms are largely the result of sympathetic neural, rather than adrenomedullary, activation. Am J Physiol Endocrinol Metab 2004;287:E32–E41.
- Jaladyan V, Darbinyan V: Insulinoma misdiagnosed as juvenile myoclonic epilepsy. Eur J Pediatr 2007;166:485–487.
- Ratcheson RA, Blank AC, Ferrendelli JA: Regionally selective metabolic effects of hypoglycemia in brain. J Neurochem 1981;36:1952–1958.
- Abdelmalik PA, Shannon P, Yiu A, Liang P, Adamchik Y, Weisspapir M, Samoilova M, Burnham WM, Carlen PL: Hypoglycemic seizures during transient hypoglycemia exacerbate hippocampal dysfunction. Neurobiol Dis 2007;26:646–660.
- Foster JW, Hart RG: Hypoglycemic hemiplegia: two cases and a clinical review. Stroke 1987;18:944–946.
- Daggett P, Nabarro J: Neurological aspects of insulinomas. Postgrad Med J 1984;60:577–581.
- Auer RN, Siesjo BK: Biological differences between ischemia, hypoglycemia, and epilepsy. Ann Neurol 1988;24:699–707.
- Gorman B, Charboneau JW, James EM, Reading CC, Galiber AK, Grant CS, van Heerden JA, Telander RL, Service FJ: Benign pancreatic insulinoma: preoperative and intraoperative sonographic localization. AJR Am J Roentgenol 1986;147:929–934.
- Gouya H, Vignaux O, Augui J, Dousset B, Palazzo L, Louvel A, Chaussade S, Legmann P: CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol 2003;181:987–992.
Article / Publication Details
Received: May 15, 2009
Accepted: October 18, 2009
Published online: December 23, 2009
Issue release date: January 2010
Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 2
ISSN: 0014-3022 (Print)
eISSN: 1421-9913 (Online)
For additional information: https://www.karger.com/ENE
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
